Symbicort SMART

A Comparison of Tolerability of 10 Inhalations of Symbicort Turbuhaler 160/4.5 mcg and 10 Inhalations of Terbutaline Turbuhaler 0.4 mg on Top of Symbicort Turbuhaler 160/4.5 mcg 1 Inhalation Bid, Randomized, Double-Blind, Cross Over, Phase III Study in Japanese Adults Asthma Patients

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220680

Enrollment

Registered

2009-02-27

Start date

2009-02-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Interventions

investigational material(s) Generic name etc : Symbicort Turbuhaler INN of investigational material : Therapeutic category code : 229 Other agents affecting respiratory organs Dosage and Administrati

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Provision of informed consent prior to any study specific procedure -A minimum of 6 months documented history of asthma according to the JGL2006/GINA2006 definition -FEV1>70% of predicted normal value pre-bronchodilator

Exclusion criteria

Exclusion criteria: -Having a known or suspected allergy to study therapy (active drugs or additive) -Having a known clinical history of hypertension, relevant arrhythmias or other heart disease, eg, ischemic heart disease, cardiomyopathy, valvular heart disease, or heart failure -Having been treated with oral, parenteral or rectal glucocorticoids within 4 weeks, or with depot parenteral glucocorticoids with 3 months -Respiratory infection significantly affecting the asthma, as judged by the investigator within 4 weeks

Design outcomes

Primary

Measure	Time frame
Adverse events, Clinical laboratory tests, ECG, Vital signs(blood pressure, pulse rate, body temperature)	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026